載入...
Requiring an amyloid-β(1-42) biomarker for prodromal Alzheimer’s disease or mild cognitive impairment does not lead to more efficient clinical trials
BACKGROUND: Low cerebrospinal fluid (CSF) amyloid-β(1-42) concentration and high total-tau/Aβ(1-42) ratio have been recommended to support the diagnosis of prodromal Alzheimer’s disease (AD) in patients with amnestic mild cognitive impairment (aMCI) and also to select patients for clinical trials. M...
Na minha lista:
| Main Authors: | , , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
2010
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2947209/ https://ncbi.nlm.nih.gov/pubmed/20813339 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jalz.2010.07.004 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|